公司概覽
業務類別 Biotechnology
業務概覽 Olema Oncology Inc is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging its deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. The company's lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), is currently in two Phase 3 clinical trials. In addition, Olema is focused in developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor.
公司地址 780 Brannan Street, San Francisco, CA, USA, 94103
電話號碼 +1 415 651-3316
傳真號碼 --
公司網頁 https://www.olema.com
員工數量 131
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Dr. Sean P. Bohen, M.D.,PhD Director, President and Chief Executive Officer 美元 699.92K 13/08/2026
Ms. Shawnte M. Mitchell, J.D. Chief Legal Officer and Corporate Secretary 美元 391.88K 29/04/2026
Dr. David C. Myles, PhD Chief Scientific Officer -- 29/04/2026
Dr. Naseem Zojwalla, M.D. Chief Medical Officer -- 29/04/2026
Mr. Jason O'Byrne Chief Financial Officer -- 13/08/2026
Ms. Sasha Lu Austin Vice President, Finance and Controller -- 16/03/2026
 
董事會成員
董事會 職務 更新日期
Mr. Andrew S. Rappaport Independent Director 29/04/2026
Ms. Cynthia M. Butitta Independent Director 29/04/2026
Mr. Ian T. Clark Chairman of the Board 29/04/2026
Dr. Sandra J. Horning, M.D. Independent Director 29/04/2026
Mr. Scott Garland Independent Director 29/04/2026
Dr. Sean P. Bohen, M.D.,PhD Director, President and Chief Executive Officer 13/08/2026
Dr. Graham Walmsley, M.D.,PhD Independent Director 29/04/2026
Ms. Yi Larson Independent Director 29/04/2026
Dr. Cyrus L. Harmon, PhD Independent Director 29/04/2026
Dr. Prakash Raman, PhD Independent Director 29/04/2026
 
所屬ETF (更新日期: 14/11/2026 02:15)
代號 名稱 佔比% ▼ 持有日期
FFSMFidelity Fundamental Small-Mid Cap ETF0.05%30/09/2026
BBCVirtus Biotech Clinical Trials ETF0.03%30/10/2026
FHLCFidelity MSCI Health Care ETF0.03%30/10/2026
IWViShares Russell 3000 ETF0.02%30/10/2026
DFUSDimensional US Equity Market ETF0.02%30/10/2026
FMEDFidelity Disruptive Medicine ETF0.02%30/10/2026
VTWGVanguard Russell 2000 Growth ETF0.02%30/09/2026
DFAUDimensional US Core Equity Market ETF0.01%30/10/2026
ISCGiShares Morningstar Small-Cap Growth ETF0.01%30/10/2026
ISCViShares Morningstar Small-Cap Value ETF0.01%30/10/2026
DCORDimensional US Core Equity 1 ETF0.01%24/09/2026
VTHRVanguard Russell 3000 ETF0.01%30/09/2026
IBBQInvesco Nasdaq Biotechnology ETF0.01%30/10/2026
RFLRInnovator U.S. Small Cp Mgd Flr ETF0.01%30/10/2026
AVSCAvantis US Small Cap Equity ETF0.01%30/10/2026
ITWOProShares Russell 2000 High Income ETF0.01%30/10/2026
BIBProShares Ultra Nasdaq Biotechnology0.004%30/10/2026
URTYProShares UltraPro Russell20000.004%30/10/2026
UWMProShares Ultra Russell20000.003%30/10/2026
WSMLiShares MSCI World Small-Cap ETF0.003%30/10/2026
  1   2    3    4  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.